Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Oxford BioTherapeutics Appoints Dr Keith E Wilson as Chief Scientific Officer

Published: Thursday, June 19, 2014
Last Updated: Thursday, June 19, 2014
Bookmark and Share
Dr Wilson brings over 20 years’ experience of life sciences research and development to the Company.

Oxford BioTherapeutics has announced the appointment of Dr Keith E Wilson as Chief Scientific Officer. Dr Wilson joins from AbbVie where he was the company’s Global Leader for Antibody Drug Conjugates.

Dr Keith E Wilson brings to Oxford BioTherapeutics over 20 years’ experience of life sciences research and development, specializing in oncology and immunology. He has extensive experience of developing and executing novel discovery, clinical and portfolio strategies, as well as providing executive-level support for corporate and business development activities.

In his most recent role, he was Director, Biologics Technology and Global Leader, Antibody Drug Conjugates at AbbVie, where he was responsible for corporate ADC strategy with multiple programs in pre-clinical and clinical development, as well as leading a large multi-functional discovery team.

Previously, he was Senior Director of Research at Facet Biotech, prior to which he was Director, Pipeline Strategy / Early Discovery and Computational Biology at PDL BioPharma. He also held positions of increasing seniority at EOS Biotechnology, where he began his industry career as a scientist.

Dr Wilson holds a PhD in Biochemistry and Molecular Biology from the Oregon Health Sciences University, and conducted post-doctoral research at Stanford University.

“I am delighted that Keith has chosen to join Oxford BioTherapeutics, where his world-class experience in leading ADC development programs will prove invaluable as we advance our pipeline into the clinic,” said Dr Christian Rohlff, Oxford BioTherapeutics’ CEO.

Commenting on his appointment, Dr Keith E Wilson, Oxford BioTherapeutics’ CSO, said, “I am highly impressed by the progress Oxford BioTherapeutics has made with its ADC programs, both scientifically and with the range and quality of the company’s technology collaborations and development partnerships. I look forward to helping the team continue this success as the company progresses its candidates into clinical development.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Oxford BioTherapeutics Grants an Exclusive License to Boehringer Ingelheim
License for development and commercialization of antibody products to an oncology target.
Thursday, January 15, 2015
Oxford BioTherapeutics Appoints Dr Eugen Leo
Dr. Leo will be responsible for driving the Company’s pipeline of ADCs into clinical development.
Thursday, July 10, 2014
Oxford BioTherapeutics Takes Exclusive Rights to Use Xenomouse® Antibodies and ADC Technology
Company to develop novel antibody-drug conjugate for HER2-negative breast cancer.
Friday, May 16, 2014
OBT and Menarini Progress Enhanced Antibody for Acute Myeloid Leukemia
First clinical development candidate in $1 billion oncology investment alliance.
Thursday, January 02, 2014
Menarini and OBT Sign Major Strategic Collaboration
Strategic alliance for the clinical development and manufacture of a portfolio of novel antibody-based cancer drugs.
Tuesday, October 30, 2012
OBT Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
Dr Begley brings extensive knowledge and expertise to OBT at an exciting phase in the company’s development.
Thursday, January 12, 2012
Scientific News
Alzheimer’s Protein Serves as Natural Antibiotic
Alzheimer's-associated amyloid plaques may be part of natural process to trap microbes, findings suggest new therapeutic strategies.
Slime Mold Reveals Clues to Immune Cells’ Directional Abilities
Study from UC San Diego identifies a protein involved in the directional ability of a slime mold.
Supressing Intenstinal Analphylaxis in Peanut Allergy
Study from National Jewish Health shows that blockade of histamine receptors suppresses intestinal anaphylaxis in peanut allergy.
Getting a Better Look at How HIV Infects and Takes Over its Host Cells
A new approach, developed by a team of researchers led by The Rockefeller University and The Aaron Diamond AIDS Research Center (ADARC), offers an unprecedented view of how a virus infects and appropriates a host cell, step by step.
Untangling Disease-Related Protein Misfolding
Work advances understanding of genetic forms of thrombosis, emphysema, cirrhosis of the liver, neurodegenerative diseases and inflammation, among others.
Developing a More Precise Seasonal Flu Vaccine
During the 2014-15 flu season, the poor match between the virus used to make the world’s vaccine stocks and the circulating seasonal virus yielded a vaccine that was less than 20 percent effective.
Fighting Cancer with Borrowed Immunity
A new step in cancer immunotherapy: researchers from the Netherlands Cancer Institute and University of Oslo/Oslo University Hospital show that even if one's own immune cells cannot recognize and fight their tumors, someone else's immune cells might.
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
Immune Cells Remember Their First Meal
Scientists at the University of Bristol have identified the trigger for immune cells' inflammatory response – a discovery that may pave the way for new treatments for many human diseases.
"Sunscreen" Gene May Guard Against Melanoma
USC-led study reveals that melanoma patients with deficient or mutant copies of the gene are less protected from harmful ultraviolet rays.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!